Transce3nd’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Transce3nd's CRSP Position: Q3 2026 in Review
Transce3nd opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 428 shares worth $21.6K. The stake represents 0.02% of the portfolio and ranks #268 among its holdings. This is a return to the name: Transce3nd previously reported a position in CRSP as recently as Q2 2025.
Transce3nd first reported a position in CRSP in Q4 2024 and has held it in 4 quarters since. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Transce3nd held 428 shares of CRISPR Therapeutics worth $21.6K as of Q3 2026.
- CRISPR Therapeutics was a new Transce3nd position in Q3 2026.
- CRISPR Therapeutics made up 0.02% of Transce3nd's portfolio in Q3 2026, its #268 holding.
- Transce3nd first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 4 quarters since.
- 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Transce3nd's 13F filing for Q3 2026, filed 26 Oct 2026.